Bioventus Inc. (NASDAQ:BVS) Given Average Rating of “Moderate Buy” by Analysts

Shares of Bioventus Inc. (NASDAQ:BVS) have earned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $16.80.

A number of equities research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price objective on shares of Bioventus in a research note on Monday, August 17th. Canaccord Genuity Group raised their target price on shares of Bioventus from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Weiss Ratings upgraded shares of Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, August 6th. Craig Hallum reaffirmed a “buy” rating and issued a $18.00 price target on shares of Bioventus in a research note on Thursday, August 6th. Finally, Barrington Research set a $18.00 price objective on shares of Bioventus in a report on Thursday, August 6th.

Bioventus Stock Performance

Shares of NASDAQ BVS opened at $14.37 on Thursday. The company has a current ratio of 1.69, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83. The stock has a 50 day simple moving average of $12.71 and a 200-day simple moving average of $10.46. The company has a market cap of $1.21 billion, a PE ratio of 18.66, a P/E/G ratio of 1.74 and a beta of 0.65. Bioventus has a 12-month low of $6.26 and a 12-month high of $15.89.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.22. Bioventus had a return on equity of 28.08% and a net margin of 9.36%.The company had revenue of $153.21 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities research analysts forecast that Bioventus will post 0.79 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd raised its position in Bioventus by 17,156.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock worth $41,000 after acquiring an additional 5,490 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of Bioventus by 147.4% in the 2nd quarter. California State Teachers Retirement System now owns 6,174 shares of the company’s stock worth $58,000 after purchasing an additional 3,678 shares during the last quarter. Prelude Capital Management LLC bought a new stake in shares of Bioventus in the 3rd quarter worth approximately $74,000. Mercer Global Advisors Inc. ADV acquired a new stake in Bioventus during the third quarter valued at approximately $78,000. Finally, Brooklyn Investment Group acquired a new stake in Bioventus during the fourth quarter valued at approximately $91,000. 62.94% of the stock is owned by institutional investors and hedge funds.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.